Visual Hallucinations in Lewy Body Diseases
Understanding Neural Mechanisms Underlying Visual Hallucinations in Lewy Body Diseases
The goal of this basic experimental study involving humans (BESH) protocol is to improve the understanding of neural mechanisms underlying visual hallucinations in Lewy Body diseases to inform future treatment developments.
Обзор исследования
Статус
Условия
Вмешательство/лечение
Подробное описание
Visual hallucinations are highly prevalent in Lewy Body Diseases (LBD), a prominent group of neurodegenerative disorders that includes Dementia with Lewy Bodies, Parkinson's disease, and Parkinson's disease dementia. Currently, scientists do not fully understand how the brain creates these false visual images. This lack of knowledge makes it difficult to develop effective treatments.
This study aims to understand the neural mechanisms that give rise to these hallucinatory experiences. The study will include three groups of volunteers:
- LBD patients who experience visual hallucinations
- LBD patients who do not have visual hallucinations
- age-matched volunteers without a significant neurological history
During the study, participants will undergo safe, non-invasive brain imaging scans. While being scanned, they will either rest or complete visual computer tasks.
The results of this study will help map the brain networks responsible for visual hallucinations. These insights will help researchers develop better, targeted interventions for this disabling symptom.
Тип исследования
Регистрация (Оцененный)
Контакты и местонахождение
Контакты исследования
- Имя: Nalini Jeet
- Номер телефона: 212-263-0228
- Электронная почта: Nalini.Jeet@nyulangone.org
Учебное резервное копирование контактов
- Имя: Yuan-hao Wu
- Номер телефона: 212.263.0307
- Электронная почта: Yuanhao.Wu@nyulangone.org
Места учебы
-
-
New York
-
New York, New York, Соединенные Штаты, 10016
- Рекрутинг
- NYU Langone Health
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Метод выборки
Исследуемая популяция
Three subject cohorts will be recruited for this study: 1) LBD patients who experience visual hallucinations (LBD-VH group); 2) patients diagnosed with LBD without any visual hallucinations (LBD-non-VH group, control arm); 3) age and demographically matched controls.
Описание
Inclusion Criteria:
I) LBD Patients with or without visual hallucinations
- 18 - 90 yrs
- Fluent in English or Spanish
- Score at least 24 out of 30 on the MoCA
- Diagnosed with Lewy Body diseases, including Parkinson's disease and Lewy Body dementias (Parkinson's disease dementia and dementia with Lewy bodies)
II) Age-matched controls (healthy volunteers)
- 18 - 90 yrs
- Fluent in English or Spanish
- Score at least 26 out of 30 on the MoCA
Exclusion Criteria:
I) LBD Patients with or without visual hallucinations
- History of traumatic brain injury or significant head trauma
- History of significant neurologic disorders other than Lewy body diseases
- Meets DSM-IV criteria for substance abuse or dependence
- For MRI studies, any contraindication to MRI as determined by the MRI Safety Screening Form
II) Age-matched controls (healthy volunteers)
- History of traumatic brain injury or significant head trauma
- History of significant neurologic disorders other than Lewy body diseases
- Meets DSM-IV criteria for substance abuse or dependence
- For MRI studies, any contraindication to MRI as determined by the MRI Safety Screening Form
Учебный план
Как устроено исследование?
Детали дизайна
- Наблюдательные модели: COHORT
- Временные перспективы: PROSPECTIVE
Когорты и вмешательства
Группа / когорта |
Вмешательство/лечение |
|---|---|
|
Patients with Lewy Body Diseases who experience visual hallucinations
Patients will complete between one and multiple outpatient experimental sessions, depending on the specific scientific question being addressed, the type of data required by the investigator and the patient's availability. Potential interventions include: behavioral tasks, MRI scans, MEG scans. |
Delivered as part of outpatient experimental sessions. Delivered as part of outpatient experimental sessions. |
|
Patients with Lewy Body Diseases who do not experience visual hallucinations
Patients will complete between one and multiple outpatient experimental sessions, depending on the specific scientific question being addressed, the type of data required by the investigator and the patient's availability. Potential interventions include: behavioral tasks, MRI scans, MEG scans. |
Delivered as part of outpatient experimental sessions. Delivered as part of outpatient experimental sessions. |
|
Age-matched controls
Patients will complete between one and multiple outpatient experimental sessions, depending on the specific scientific question being addressed, the type of data required by the investigator and the patient's availability. Potential interventions include: behavioral tasks, MRI scans, MEG scans. |
Delivered as part of outpatient experimental sessions. Delivered as part of outpatient experimental sessions. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Changes in recognition rate
Временное ограничение: Pre-Disambiguation Stage, Post-Disambiguation Stage (Study Visit: 1 Day)
|
Behavioral responses assessed by changes in recognition rate from pre- to post-disambiguation stage. |
Pre-Disambiguation Stage, Post-Disambiguation Stage (Study Visit: 1 Day)
|
|
Euclidean distance in neural activity patterns
Временное ограничение: Pre-Disambiguation Stage, Post-Disambiguation Stage (Study Visit: 1 Day)
|
Neural response patterns assessed by Euclidean distance in neural activity pattern between pre- and post-disambiguation stages. |
Pre-Disambiguation Stage, Post-Disambiguation Stage (Study Visit: 1 Day)
|
Соавторы и исследователи
Спонсор
Следователи
- Главный следователь: Biyu He, PhD, NYU Langone Health
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
- Синуклеинопатии
- Неврологические проявления
- Заболевания головного мозга
- Заболевания центральной нервной системы
- Заболевания нервной системы
- Психические расстройства
- Нейроповеденческие проявления
- Нейрокогнитивные расстройства
- Слабоумие
- Нейродегенеративные заболевания
- Двигательные расстройства
- Паркинсонические расстройства
- Заболевания базальных ганглиев
- Расстройства восприятия
- Патологические состояния, признаки и симптомы
- Признаки и симптомы
- Болезнь Паркинсона
- Болезнь с тельцами Леви
- Галлюцинации
Другие идентификационные номера исследования
- 15-01323
- 1R01NS148898 (Грант/контракт NIH США)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
The de-identified participant data from the final research dataset will be shared upon reasonable request by the time of publication or, the end of the period of performance, including any no-cost extension. Data will remain available for at least as long as required by the applicable repository and/or journal policies. De-identified behavioral and fMRI data underlying peer-reviewed publications will be shared through established repositories, such as OpenNeuro, GitHub, and figshare. Data will be shared by the time of publication or, for other findings, by the end of the award's period of performance, and will remain available for at least as long as required by the applicable repository and/or journal policies. Repository links will be provided when available. All potentially identifying information will be fully removed prior to releasing the data.
Сроки обмена IPD
Data will become available by the time of publication or, the end of the period of performance, including any no-cost extension. Data will remain available for at least as long as required by the applicable repository and/or journal policies.
Критерии совместного доступа к IPD
The investigator who proposes to use the data will be granted access upon reasonable request. De-identified behavioral and fMRI data underlying peer-reviewed publications will be shared through established repositories, such as OpenNeuro, GitHub, and figshare. Data will be shared by the time of publication or, for other findings, by the end of the award's period of performance, and will remain available for at least as long as required by the applicable repository and/or journal policies. Repository links will be provided when available
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .